As of today (2024-04-24), Eterna Therapeutics's share price is $1.96. Eterna Therapeutics's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $0.04. Hence, Eterna Therapeutics's Price to Tangible Book Ratio of today is 56.00.
The historical rank and industry rank for Eterna Therapeutics's Price-to-Tangible-Book or its related term are showing as below:
ERNA'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.64 Med: 12.42 Max: 61.14
Current: 49
During the past 4 years, Eterna Therapeutics's highest Price to Tangible Book Ratio was 61.14. The lowest was 1.64. And the median was 12.42.
ERNA's Price-to-Tangible-Book is ranked worse than 98.36% of 1218
companies
in the Biotechnology industry
Industry Median: 2.69
vs ERNA: 49.00
A closely related ratio is called PB Ratio. As of today, Eterna Therapeutics's share price is $1.96. Eterna Therapeutics's Book Value per Sharefor the quarter that ended in Dec. 2023 was $0.41. Hence, Eterna Therapeutics's P/B Ratio of today is 4.75.
Eterna Therapeutics Price-to-Tangible-Book Historical Data
The historical data trend for Eterna Therapeutics's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Eterna Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eterna Therapeutics Price-to-Tangible-Book Distribution
For the Biotechnology industry and Healthcare sector, Eterna Therapeutics's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Eterna Therapeutics's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Eterna Therapeutics Price-to-Tangible-Book Related Terms
Thank you for viewing the detailed overview of Eterna Therapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.
Eterna Therapeutics (Eterna Therapeutics) Business Description
Eterna Therapeutics Inc is a biopharmaceutical company. The company develops transformational new medicines using various cell engineering technology. It is engaged in developing breakthrough mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. With its strategic partners, the group is developing nucleic acid and cell therapies that can significantly improve the health outcomes of patients with high unmet medical needs.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ERNA has been successfully added to your 